Analysis of TGF-β Gene Expression in Carboplatin Treated Lung Cancer Cells

Cancer, characterized by uncontrolled cell growth, remains a formidable challenge in modern medicine.Among various treatment modalities, chemotherapy, a systemic approach using drugs to impede cancer cell proliferation, is a cornerstone of cancer therapy.This study aimed to analyze the trends in TGF- gene expression in carboplatin-treated lung cancer cell line A549.The materials and methods included an MTT assay to assess cell survivability, RNA isolation using the TRIzol method, and further analysis by RT-PCR, with data statistically analyzed using SPSS software.Results showed that TGF- gene expression was significantly lower in the A549 cell line treated with carboplatin compared to the untreated cell line.Specifically, the treated cells exhibited a 40% reduction in TGF- expression, a statistically significant decrease (p < 0. 05). Given that TGF- is known to promote tumorigenesis, the observed reduction suggests that carboplatin may control tumor progression by downregulating TGF- expression and the proliferation of cancer cells. In conclusion, our study demonstrates the effectiveness of carboplatin as a chemotherapy agent in inhibiting the proliferation of lung cancer cells (A549) in non-small cell lung cancer (NSCLC) by reducing TGF- gene expressionlevels.These findings underscore the potential of carboplatin to modulate gene expression associated with tumor growth, offering a promising therapeutic strategy for NSCLC management.Future studies should explore the broader implications of TGF- modulation in cancer treatment and investigate the potential of combining carboplatin with other therapeutic agents to enhance its efficacy.